Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

LONGHEART

Financiado

Cerrado

Exploring selected long non coding RNAs as diagnostics and therapeutic targets...

Exploring selected long non coding RNAs as diagnostics and therapeutic targets for heart failure Despite clinical advances, diseases of the cardiovascular system are the most common cause of morbidity and mortality in the EU with currently 50 million people suffering from heart failure. These important challenges call for a b... ver más

31/05/2021

MHH

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

MEDIZINISCHE HOCHSCHULE HANNOVER No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-05-31

ERC-CoG-2014: ERC Consolidator Grant

I+D

Cerrada hace 10 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

MHH

1.82M€ | Lider

HOGAR DIGITAL S.L

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

MIRAGE MicroRNAs as therapeutic targets for ARVC. 166K€ Cerrado

CodingHeart Novel Coding Factors in Heart Disease 2M€ Cerrado

GLIA-LNC Long non coding RNAs that regulate glial cell function in th... 163K€ Cerrado

B-specific B-specific: B-cell related gene and protein markers with pro... 4M€ Cerrado

MEGFIB Noncoding RNA MEG3 inhibitor for Heart Failure Treatment 150K€ Cerrado

ROLE OF CARDIAC SOX6 Deciphering the functions of Sox6 and myosin encoded microRN... 222K€ Cerrado

Duración del proyecto: 72 meses Fecha Inicio: 2015-05-07
Fecha Fin: 2021-05-31

Líder del proyecto

MEDIZINISCHE HOCHSCHULE HANNOVER No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Despite clinical advances, diseases of the cardiovascular system are the most common cause of morbidity and mortality in the EU with currently 50 million people suffering from heart failure. These important challenges call for a better understanding of underlying mechanisms to enable development of innovative, effective diagnostic and therapeutic strategies for heart failure. Cardiac stress such as myocardial infarction or hypertension leads to cellular remodeling of the left ventricle resulting in heart failure. Protein-coding genes originate from only 1.5% of the genome, whereas the larger remaining portion is often transcribed to non-coding RNAs, of which functional importance is still ill understood. We pioneered a role of small microRNAs as diagnostics and therapeutic targets for heart failure (Nature, 2008; Nature Comm, 2012, J Clin Invest, 2014). We now will focus on the larger fraction of long non-coding RNAs (lncRNAs) and their functional roles, as well as diagnostic and therapeutic use in heart failure. The proposal has the following interconnected objectives: a) identify novel functional relevant cardiac remodeling-associated lncRNAs; b) characterise key lncRNA cardiac targetomes; c) investigate lncRNA-paracrine mechanisms and the diagnostic and prognostic potential of cardiac-derived extracellular lncRNAs using large clinical cohorts; and d) discover their therapeutic potential to prevent cardiac remodeling in clinically relevant animal models. Innovative molecular and cell-based methods, a unique lncRNA-shRNA library, genetic animal models and availability of large clinical biobanks will form the basis for a successful strategy. LONGHEART will lead to ground-breaking new insight into the role of lncRNAs in the heart. These findings will firmly establish lncRNA-based mechanisms to identify fundamentally novel diagnostic and therapeutic entry points for a most serious clinical important disorder in dire need for new diagnostic and therapeutic paradigms.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores